TMBRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 11月 2023 @ 05:59):

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases...

Stats
本日の出来高	130 464
平均出来高	107 900
時価総額	1.18M
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.174
ATR14	$0.215 (2 128.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-20	Koconis John	Buy	70 385	Common Stock, par value $0.001 per share
2023-08-20	Mendelsohn Alan	Buy	35 193	Common Stock, par value $0.001 per share
2023-08-20	Lucchese Joseph	Buy	35 193	Common Stock, par value $0.001
2023-04-15	Koconis John	Buy	45 010	Stock Option (right to buy)
2023-04-15	Gaal Lubor	Buy	4 100	Common Stock, par value $0.001 per share

INSIDER POWER
100.00
Last 85 transactions
Buy: 16 585 051 \| Sell: 6 873 671

ボリューム相関

長: 0.06 (neutral)

短: -0.33 (neutral)

Signal:(23.664) Neutral

Timber Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Timber Pharmaceuticals 相関 - 通貨/商品

-0.45
( neutral )

-0.70
( moderate negative )

-0.29
( neutral )

-0.74
( moderate negative )

-0.28
( neutral )

0.48
( neutral )

Timber Pharmaceuticals 財務諸表

Annual	2022
収益:	$83 177.00
総利益:	$-13.22M (-15 892.35 %)
EPS:	$-9.19

FY	2022
収益:	$83 177.00
総利益:	$-13.22M (-15 892.35 %)
EPS:	$-9.19

FY	2021
収益:	$886 532
総利益:	$886 532 (100.00 %)
EPS:	$-34.30

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-48.15

Financial Reports:

No articles found.

Timber Pharmaceuticals

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.